fingolimod has been researched along with Autoimmune Diseases in 5 studies
*Autoimmune Diseases: Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Don, AS; Martinez-Lamenca, C; Proia, RL; Roberts, E; Rosen, H; Webb, WR | 1 |
| Augeri, DJ; Bagdanoff, JT; Barbosa, J; Baugh, SD; Bednarz, M; Bruce, D; Carlsen, M; Carson, KG; Courtney, LF; Digeorge-Foushee, AM; Donoviel, MS; Fu, Q; Gardyan, M; Gopinathan, S; Hazelwood, J; Jessop, TC; Kimball, SD; Kramer, J; Lai, Z; Layek, S; Liu, Q; Main, A; Moran, L; Nguyen, H; Nouraldeen, A; O'Neill, E; Oravecz, T; Smith, T; Sun, W; Swaffield, J; Tarver, J; Taylor, J; Terranova, KM; Wilson, A; Yan, J; Yu, S; Zhang, H | 1 |
| Al-Shamma, H; Barden, J; Buzard, DJ; Calderon, I; Chen, C; Edwards, J; Espinola, S; Fu, L; Gao, Y; Gatlin, J; Gharbaoui, T; Han, S; Jones, RM; Kawasaki, A; Krishnan, A; Le, M; Lehmann, J; Liu, L; Lopez, L; Moody, J; Morgan, M; Sadeque, A; Sengupta, D; Solomon, M; Thatte, J; Thoresen, L; Ullman, B; Usmani, K; Whelan, K; Xing, C; Zhu, X | 1 |
| Camp, SM; Garcia, JGN; Marciniak, A; Polt, R | 1 |
| Carter, PH; Cornelius, G; Cvijic, ME; Dhar, TGM; Dyckman, AJ; Gilmore, JL; Lehman-McKeeman, LD; Levesque, PC; Marino, AM; Mathur, A; McIntyre, KW; Pang, J; Salter-Cid, L; Shen, DR; Shi, H; Sun, H; Taylor, TL; Warrack, BM; Xiao, HY; Xiao, Z; Xie, J; Yang, M; Yang, X | 1 |
1 review(s) available for fingolimod and Autoimmune Diseases
| Article | Year |
|---|---|
An update on sphingosine-1-phosphate receptor 1 modulators.
Topics: Autoimmune Diseases; Biological Availability; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Oxadiazoles; Receptors, Lysosphingolipid; Sphingolipids | 2018 |
4 other study(ies) available for fingolimod and Autoimmune Diseases
| Article | Year |
|---|---|
Essential requirement for sphingosine kinase 2 in a sphingolipid apoptosis pathway activated by FTY720 analogues.
Topics: Animals; Apoptosis; Autoimmune Diseases; bcl-2-Associated X Protein; Calcium Signaling; Caspases; Cell Membrane Permeability; Drug Resistance, Neoplasm; Endoplasmic Reticulum; Fingolimod Hydrochloride; HeLa Cells; Humans; Immunosuppressive Agents; Jurkat Cells; Lymphoproliferative Disorders; Mice; Mice, Knockout; Mitochondria; Mutagenesis; Organ Specificity; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Protein Transport; Receptors, Lysosphingolipid; Sphingolipids; Sphingosine; Spleen; Thymus Gland | 2007 |
Inhibition of sphingosine-1-phosphate lyase for the treatment of autoimmune disorders.
Topics: Administration, Oral; Aldehyde-Lyases; Animals; Autoimmune Diseases; Enzyme Inhibitors; Imidazoles; Lymphocyte Count; Mice; Structure-Activity Relationship | 2009 |
Fused tricyclic indoles as S1P₁ agonists with robust efficacy in animal models of autoimmune disease.
Topics: Animals; Autoimmune Diseases; Disease Models, Animal; Female; Humans; Immunologic Factors; Indoles; Lymphocytes; Male; Mice; Mice, Inbred C57BL; Microsomes; Rats; Rats, Sprague-Dawley; Receptors, Lysosphingolipid; Structure-Activity Relationship | 2012 |
Bicyclic Ligand-Biased Agonists of S1P
Topics: Animals; Arthritis, Experimental; Autoimmune Diseases; Biotransformation; Bridged Bicyclo Compounds; Bronchoalveolar Lavage Fluid; Chemotaxis, Leukocyte; Drug Evaluation, Preclinical; Half-Life; Humans; Lung Diseases; Male; Myocytes, Cardiac; Phosphorylation; Proprotein Convertases; Rats; Rats, Inbred Lew; Serine Endopeptidases; Structure-Activity Relationship | 2021 |